Cargando…

A de novo MAPRE2 variant in a patient with congenital symmetric circumferential skin creases type 2

BACKGROUND: Congenital symmetric circumferential skin creases (CSCSC) was initially described five decades ago. Exome sequencing has recently revealed the genetic etiology of CSCSC. Pathogenic variants in TUBB (OMIM# 191130) and MAPRE2 (OMIM# 605789) have been linked to CSCSC1 (OMIM# 156610) and CSC...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Jincai, Lan, Xiaoping, Shen, Jun, Song, Xiaozhen, Tang, Xiaojun, Xu, Wuhen, Ren, Xiang, Zhang, Hong, Yu, Guangjun, Wu, Shengnan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005612/
https://www.ncbi.nlm.nih.gov/pubmed/31903734
http://dx.doi.org/10.1002/mgg3.1096
_version_ 1783494973573824512
author Feng, Jincai
Lan, Xiaoping
Shen, Jun
Song, Xiaozhen
Tang, Xiaojun
Xu, Wuhen
Ren, Xiang
Zhang, Hong
Yu, Guangjun
Wu, Shengnan
author_facet Feng, Jincai
Lan, Xiaoping
Shen, Jun
Song, Xiaozhen
Tang, Xiaojun
Xu, Wuhen
Ren, Xiang
Zhang, Hong
Yu, Guangjun
Wu, Shengnan
author_sort Feng, Jincai
collection PubMed
description BACKGROUND: Congenital symmetric circumferential skin creases (CSCSC) was initially described five decades ago. Exome sequencing has recently revealed the genetic etiology of CSCSC. Pathogenic variants in TUBB (OMIM# 191130) and MAPRE2 (OMIM# 605789) have been linked to CSCSC1 (OMIM# 156610) and CSCSC2 (OMIM# 616734), respectively, in an autosomal dominant manner. Four pathogenic variants in MAPRE2 have been previously reported to be associated with CSCSC2. METHODS: Whole‐exome sequencing (WES) has been performed and an in‐house pipeline was used to conduct a phenotype‐driven data analysis. All candidate variants were confirmed by Sanger sequencing. RESULTS: Here we report a 2‐year‐old boy characterized by absent expressive speech, normal to mild over growth, facial dysmorphic features, remarkable circumferential skin creases on both forearms and ankles. WES disclosed a de novo missense MAPRE2 variant, c.518G>A (p.Arg173Gln), as the molecular cause of this complex phenotype. We described detailed clinical characterization of this patient and compared the available clinical data of individuals with MAPRE2 variants to demonstrate the phenotypic spectrum. CONCLUSION: Our study reports the first patient of Asian origin with CSCSC2 due to a pathogenic mutation of MAPRE2 and expands the clinical and genetic spectrum of CSCSC2.
format Online
Article
Text
id pubmed-7005612
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-70056122020-02-13 A de novo MAPRE2 variant in a patient with congenital symmetric circumferential skin creases type 2 Feng, Jincai Lan, Xiaoping Shen, Jun Song, Xiaozhen Tang, Xiaojun Xu, Wuhen Ren, Xiang Zhang, Hong Yu, Guangjun Wu, Shengnan Mol Genet Genomic Med Original Articles BACKGROUND: Congenital symmetric circumferential skin creases (CSCSC) was initially described five decades ago. Exome sequencing has recently revealed the genetic etiology of CSCSC. Pathogenic variants in TUBB (OMIM# 191130) and MAPRE2 (OMIM# 605789) have been linked to CSCSC1 (OMIM# 156610) and CSCSC2 (OMIM# 616734), respectively, in an autosomal dominant manner. Four pathogenic variants in MAPRE2 have been previously reported to be associated with CSCSC2. METHODS: Whole‐exome sequencing (WES) has been performed and an in‐house pipeline was used to conduct a phenotype‐driven data analysis. All candidate variants were confirmed by Sanger sequencing. RESULTS: Here we report a 2‐year‐old boy characterized by absent expressive speech, normal to mild over growth, facial dysmorphic features, remarkable circumferential skin creases on both forearms and ankles. WES disclosed a de novo missense MAPRE2 variant, c.518G>A (p.Arg173Gln), as the molecular cause of this complex phenotype. We described detailed clinical characterization of this patient and compared the available clinical data of individuals with MAPRE2 variants to demonstrate the phenotypic spectrum. CONCLUSION: Our study reports the first patient of Asian origin with CSCSC2 due to a pathogenic mutation of MAPRE2 and expands the clinical and genetic spectrum of CSCSC2. John Wiley and Sons Inc. 2020-01-05 /pmc/articles/PMC7005612/ /pubmed/31903734 http://dx.doi.org/10.1002/mgg3.1096 Text en © 2019 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Feng, Jincai
Lan, Xiaoping
Shen, Jun
Song, Xiaozhen
Tang, Xiaojun
Xu, Wuhen
Ren, Xiang
Zhang, Hong
Yu, Guangjun
Wu, Shengnan
A de novo MAPRE2 variant in a patient with congenital symmetric circumferential skin creases type 2
title A de novo MAPRE2 variant in a patient with congenital symmetric circumferential skin creases type 2
title_full A de novo MAPRE2 variant in a patient with congenital symmetric circumferential skin creases type 2
title_fullStr A de novo MAPRE2 variant in a patient with congenital symmetric circumferential skin creases type 2
title_full_unstemmed A de novo MAPRE2 variant in a patient with congenital symmetric circumferential skin creases type 2
title_short A de novo MAPRE2 variant in a patient with congenital symmetric circumferential skin creases type 2
title_sort de novo mapre2 variant in a patient with congenital symmetric circumferential skin creases type 2
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005612/
https://www.ncbi.nlm.nih.gov/pubmed/31903734
http://dx.doi.org/10.1002/mgg3.1096
work_keys_str_mv AT fengjincai adenovomapre2variantinapatientwithcongenitalsymmetriccircumferentialskincreasestype2
AT lanxiaoping adenovomapre2variantinapatientwithcongenitalsymmetriccircumferentialskincreasestype2
AT shenjun adenovomapre2variantinapatientwithcongenitalsymmetriccircumferentialskincreasestype2
AT songxiaozhen adenovomapre2variantinapatientwithcongenitalsymmetriccircumferentialskincreasestype2
AT tangxiaojun adenovomapre2variantinapatientwithcongenitalsymmetriccircumferentialskincreasestype2
AT xuwuhen adenovomapre2variantinapatientwithcongenitalsymmetriccircumferentialskincreasestype2
AT renxiang adenovomapre2variantinapatientwithcongenitalsymmetriccircumferentialskincreasestype2
AT zhanghong adenovomapre2variantinapatientwithcongenitalsymmetriccircumferentialskincreasestype2
AT yuguangjun adenovomapre2variantinapatientwithcongenitalsymmetriccircumferentialskincreasestype2
AT wushengnan adenovomapre2variantinapatientwithcongenitalsymmetriccircumferentialskincreasestype2
AT fengjincai denovomapre2variantinapatientwithcongenitalsymmetriccircumferentialskincreasestype2
AT lanxiaoping denovomapre2variantinapatientwithcongenitalsymmetriccircumferentialskincreasestype2
AT shenjun denovomapre2variantinapatientwithcongenitalsymmetriccircumferentialskincreasestype2
AT songxiaozhen denovomapre2variantinapatientwithcongenitalsymmetriccircumferentialskincreasestype2
AT tangxiaojun denovomapre2variantinapatientwithcongenitalsymmetriccircumferentialskincreasestype2
AT xuwuhen denovomapre2variantinapatientwithcongenitalsymmetriccircumferentialskincreasestype2
AT renxiang denovomapre2variantinapatientwithcongenitalsymmetriccircumferentialskincreasestype2
AT zhanghong denovomapre2variantinapatientwithcongenitalsymmetriccircumferentialskincreasestype2
AT yuguangjun denovomapre2variantinapatientwithcongenitalsymmetriccircumferentialskincreasestype2
AT wushengnan denovomapre2variantinapatientwithcongenitalsymmetriccircumferentialskincreasestype2